InChI
1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
SMILES string
CC(C)N(CCC(C(N)=O)(c1ccccc1)c2ccccn2)C(C)C
InChI key
UVTNFZQICZKOEM-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
disopyramide
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Disopyramide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
IA 类抗心律失常药；钠通道阻断剂
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
J P Fauchier et al.
Archives des maladies du coeur et des vaisseaux, 84(4), 553-560 (1991-04-01)
Moricizine chlorhydrate (Ethmozine), a relatively unknown antiarrhythmic agent in France, is a derivative of Phenothiazine, related to the Vaughan-Williams Class IB drugs. A randomised, double-blind, crossover trial with Disopyramide 600 mg/day after a placebo period in 10 patients with ventricular
Procainamide and disopyramide.
C Ribeiro et al.
European heart journal, 8 Suppl A, 11-19 (1987-03-01)
Pharmacokinetics and pharmacodynamics of disopyramide.
J Bonde
Danish medical bulletin, 38(2), 121-133 (1991-04-01)
T Tokudome et al.
Angiology, 50(4), 331-335 (1999-05-04)
The effect of intravenous administration of disopyramide (total dose 100 mg, bolus 20 mg every 5 minutes) was compared with that of propranolol (total dose 10 mg, bolus 2 mg every 5 minutes) in a patient with hypertrophic obstructive cardiomyopathy.
M S Croxson et al.
The New Zealand medical journal, 100(827), 407-408 (1987-07-08)
A patient treated with disopyramide presented with hypoglycaemia, a raised serum insulin level and died of pneumonia. From these findings and a review of 10 case reports, we propose that disopyramide causes hypoglycaemia by stimulation of insulin release as described
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持